Friday, 16 October 2026European Markets

ELLIPTIC LABORATOR Stock Impressive Drop 13% At Session Start On Friday, Underperforms Market

Loading stream...

(VIANEWS) - Shares of ELLIPTIC LABORATOR (Oslo Børs All-share Index_GI: ELABS.OL) dropped by a staggering 13.97% to kr16.50 at 10:25 EST on Friday, after two consecutive sessions in a row of losses. Oslo Børs All-share Index_GI is dropping 0.78% to kr1,405.92, after five sequential sessions in a row of losses. This seems, as yet, a somewhat bearish trend trading session today.

About ELLIPTIC LABORATOR

Elliptic Laboratories ASA, an artificial intelligence (AI) software company, provides AI virtual smart sensors for the smartphone, laptop, Internet of Things, and automotive industries. The company offers AI Virtual Presence Sensor, a presence-detection solution used to improve the security of data stored on laptops; AI Virtual Proximity Sensor that enables exquisite full-screen devices; 3D touchless gesture support service; AI Virtual Gesture Sensor, a touch-free ultrasound gesture technology; AI Virtual Presence Sensor, which delivers presence-sensing capabilities to various devices that possesses a speaker, microphone, and audio processor; and AI Virtual Connection Sensor that allows to pair and authenticate smart devices in the same room. It serves in Norway, China, Taiwan, South Korea, the United States, and Japan. The company was incorporated in 2006 and is headquartered in Oslo, Norway.

Earnings Per Share

As for profitability, ELLIPTIC LABORATOR has a trailing twelve months EPS of kr-1.4.

Volume

Today's last reported volume for ELLIPTIC LABORATOR is 1083442 which is 615.89% above its average volume of 151340.

Volatility

ELLIPTIC LABORATOR's last week, last month's, and last quarter's current intraday variation average was a positive 0.69%, a negative 0.58%, and a positive 2.51%.

ELLIPTIC LABORATOR's highest amplitude of average volatility was 2.01% (last week), 1.50% (last month), and 2.51% (last quarter).

More news about ELLIPTIC LABORATOR (ELABS.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com